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The mouse is extensively used as a model system to
reproducehumandiseases in amammalian system, and to
consequently allow to examine the molecular and patho-
genic features of the disease in a context that is as close as
possible to the human being. The use of the mouse has
been particularly useful in three large areas of experi-
mental pathogenesis: (1) classic monogenic diseases, (2)
cancer development and progression and (3) develop-
mental genetics and congenital pathologies. In each of
these areas, significant progress has been made in recent
years.Here,aftera short introductionto thebiologyof the
mouse and its history as amodel organism,we summarise
the current status of genetic manipulation of the mouse
genome, provide an overview of current knowledge and
illustrate some recent advancements.
The Mouse as a Model
The house mouseMus musculus plays a prominent role in
the field of functional genetics since the rebirth of the
subject at the beginning of the twentieth century. Owing to
its long history of domestication as a pet, mice with various
coat colour and other visible features were selected and
bred over the centuries. New traits appeared suddenly in
captive-bred animals, often due to single gene mutations.
Early animal geneticists appreciated the importance of the
genetic resource becoming available and these animals
were quickly used to extend the validity ofMendel’s laws to
mammals. See also: Evolution during Domestication;
Mutations and New Variation: Overview
Mice represent the model of choice for genetic studies in
mammals. There are a number of compelling reasons for
this: that they can be hosted in small rooms due to their size,
have a short generation time (8–9 weeks), breed readily in
captivity and are highlyprolific (8–12pups eachpregnancy).
Importantly, due to the high conservation of their genomes,
results from the mouse can often be translated to humans,
not without exceptions. After centuries of selection, easy-
to-handle normal and mutant strains are widespread
and represent an extraordinary resource for genetic studies.
See also: Experimental Organisms Used in Genetics
Life cycle and fertilisation
Embryonic development of the mouse is completed in 21
days, fertility is reached in 5–6 weeks and the average
lifespan is 2 years. Several features of their development,
before and after birth, are remarkably similar with that of
humans. See also: Reproduction in Mammals: General
Overview
In male mice the spermatozoans are produced continu-
ously in large numbers throughout adult life. Female germ-
line cells, instead, are generated in a fixed number since
birth (approximately 50 000). Primordial female germ cells
initiate meiosis, arrest at the prophase of the first meiotic
division, and remain suspended forweeks (years inwomen)
until puberty. The female mouse will undergo an oestrous
cycle during which 8–10 primary oocytes complete the
first meiotic division and initiate the second meiotic div-
ision; the oocyte is then ovulated, descends the oviducts
and is receptive to fertilisation for a short period of time.
See also: Reproduction in Eutherian Mammals
Fertilisation occurs when a sperm cell fuses its cell
membrane with the oocyte membrane, giving rise to a bi-
nucleated diploid cell, the zygote, which represents the
earliest (1 cell) stage of a new individual. See also: Sperm–
Egg Interactions: Sperm–Egg Binding in Mammals
Fertilisation often produces more zygotes than those
that complete development. In mammals, in particular,
zygotes that initiate development not necessarily succeed in
the subsequent implantation andwill be lost. Several causes
have been implicated, one of these is the presence of genetic
mutations or chromosomal anomalies in the zygote, that
are being selected against by natural selection.
Pre-implantation development
Mammalian development is divided into two stages, sep-
arated by the moment of implantation into the uterus. The
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pre-implantation stage lasts 4.5 days, during which the
zygote is hosted within the mother’s oviduct. The zygotes
can be easily collected, kept in culture for hours and used
for genetic manipulation, without losing their ability to
generate a new individual upon reintroduction into a
female oviduct. Once the embryo has undergone implant-
ation, it can no longer be removed from its mother’s body.
The accessibility of the pre-implantation embryo provides
the basis for a number of specialised genetic tools that are
used to study mammalian development (see next sections).
See also: Mouse Early Development: Molecular Basis
Within the pre-implantation zygote the highly com-
pacted sperm genome into a paternal pronucleus expands
to match the size of the maternal pronucleus. In the next
60 hours, the zygote undergoes cleavage, that is, four
equal divisions that generate a 16-cell embryo, known as
morula. During cleavage, all of the cells in the developing
embryo are equivalent and totipotent, a term used to
describe a cell that is fully undifferentiated and retains the
ability (or potency) to generate each and every cell type of
the embryo and of the adult animal. As a proof of this,
cleavage stage embryos can be separated into individual
cells, each able to generate a full individual upon reim-
plantation. This process occurs spontaneously in humans,
giving rise to genetically identical twins. See also:Cleavage
and Gastrulation in Mouse Embryos; Whole Animal
Cloning
After the morula stage the first specialisation occurs, the
potency of individual cells becomes progressively
restricted, while cells continue to divide and increase in
number. The outer cells of the morula give rise to the tro-
phoectoderm, which will take part in the formation of the
placenta, while the inner cells compact into a clump at one
pole of the sphere. These cells, known as inner cell mass
(ICM) are now pluripotent, will develop into the fetus but
have lost the ability to generate a trophoectoderm. At this
stage of development, the embryo is called a blastocyst.
Implantation initiates the development of the placenta, a
combination of embryonic and maternal tissues that
mediates the bi-directional flow of nutrients, oxygen and
waste products between the mother and embryo.
Post-implantation development
Following implantation, a period of rapid organisation,
organ formation and growth begins. Cells from the
ICM first organise into three cell layers (ectoderm, endo-
derm andmesoderm) via a morphogenetic phase known as
gastrulation. Next, the general body plan and its sub-
division are laid out, then the primordia of the brain and
spinal cord, heart, sensory organs, cranial and axial skel-
eton are put into place, and the morphogenesis and
differentiation of the various tissues and organs initiates.
The fetus continues to grow in size, until birth. More
information on the biology of mammalian development in
section ‘Genetic diseases leading to developmental/con-
genital malformations’.
The Mouse Genome and its
Manipulation
The haploid genomes of humans and mice contain
approximately 3 billion base pairs of deoxyribonucleic acid
(DNA),with striking similarities revealeduponcompletion
of their respective sequencing projects. See also: Human
Genome Project, HUGO and Future Health Care; Human
Genome Project: Importance in Clinical Genetics
Indeed, most human genes have a corresponding
homologue in the mouse genome, named ‘hortholog’.
Thus, themouse genomeprovides a powerfulmodel system
for investigating the genetic basis of both simple and
complex human traits, especially those related to devel-
opment and disease. Conversely, most differences consist
in species-specific additions to gene families that already
existed in the common ancestor, or in noncoding
sequences.
The mouse genome is contained within 19 autosomes
and two sex chromosomes. Although human and mouse
karyotypes do not show any evidence of chromosome
banding homologies, genes that are closely linked in one
species (synthenic) are usually found to be closely linked in
the other (conserved syntheny). By comparing the genetic
maps comprising the whole mouse genome with those of
the human genome, it becomes evident that syntheny
extends across nearly the complete karyotype. See also:
Evolution of Genome Organization; Genome Evolution:
Overview; Genome Mapping; Genome Organization of
Vertebrates
Conserved syntheny has strong evolutionary impli-
cations, but just as importantly, it serves as a critical tool
for identifying noncoding regions of the genome that are
nevertheless conserved, and thus likely to play regulatory
roles. See also: Genetic and Physical Map Correlation
The first evidence that mice could represent valuable
disease models came from the analysis of spontaneous
mutations arising in breeding colonies. This is for example
the case of the leptin gene, whose mutation is involved in
obesity, and of the gene encoding for the Fas receptor,
involved in auto-immunity. See also: Apoptosis: Inherited
Disorders; Human Disease: Mouse Models; Mouse as a
Model for Human Diseases; Obesity: Genetics
By far the most useful strategy has however been that
known as ‘reverse genetics’, whereby a gene of interest is
studied and characterised in vivo via its introduction or
modification in the mouse genome. There are three main
approaches to manipulate the mouse genome: (1) the gen-
eration of transgenic mice, whereby an exogenous
sequence, called a transgene, is inserted within the mouse
genome; (2) targeted mutagenesis, consisting in the inser-
tion of genetic material at specific locations via a process
known as homologous recombination, resulting in the
inactivation ormodification of the chosen gene; and (3) the
two approaches above combined in strategies that only
induce the genetic modification in certain cells and at cer-
tain times, known as ‘conditional mutagenesis’. These
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approaches are depicted in Figure 1, together with some of
their most common research applications.
Generation of transgenic mice
In 1981, Frank Costantini and Elizabeth Lacy published a
protocol for inserting foreign DNA into the mouse germ-
line; this drastically changed our approach to mammalian
genetics and has so far provided a wealth of knowledge,
not obtainable otherwise (Costantini and Lacy, 1981). To
generate a transgenic mouse – with a novel DNA sequence
integrated into one of its chromosomes – the foreign DNA
is injected into the male pronucleus of a one-cell embryo,
and the embryo is then transferred into a pseudo-pregnant
female to allow development to proceed. Up to 50% of the
mice born from injected embryos will carry multiple copies
of the foreign DNA stably integrated into their genomes
and will transmit this DNA onto their progeny. See also:
Transgenic Animals; Transgenic Mice; Transgenic Mice
Production
The recombinant DNA construct has to contain specific
sequences in order to be transcribed and translated. In
particular, the coding sequence must be placed under the
control of suitable eukaryotic regulatory regions, knownas
promoter and enhancer, followed by a polyadenylation
signal. Furthermore, the transgene should contain at least
Injection of foreign DNA
Transgenic models Gene functions, dominant
Gene regulation
Disease model
Pathway reporter
Injection of modified ES cells
(a)
(b)
(c)
(d)
Knock-out models
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deleter mice
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Structure/function
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Figure 1 Manipulating the mouse genome: where, when and why. A scheme to summarise the three principal genetic manipulation and the phenotypic
studies that are most commonly performed, in relation with developmental and post-natal stages of the mouse. On the left, a photographic description of
the various embryonic stages considered. On the right, the manipulations required to generate the different models and the modified strains that can be
obtained: (a) injection of foreign DNA to generate transgenic models, reproduced from Dr. Hirsch, University of Torino, (b) injection of modified ES cells to
generate knock-out and conditional models, reproduced from Dr. Hirsch, University of Torino and (c, d) cross-breeding with Cre-expressing animals to carry
out somatic cell genetics. For each of these strategies, a short list of common research applications is reported.
Mice as Experimental Organisms
eLS & 2012, John Wiley & Sons, Ltd. www.els.net 3
one intronic region, required to stabilise the transcribed
ribonucleic acid (RNA). The main limit of this technology
is the random integration of the transgene in the host
genome. The chromosomal region of insertion can alter the
expression of the transgene either by repressing it, as is the
case of heterochromatic, silent genomic regions, or by
improperly activating it. Another serious problem is that of
insertional mutagenesis, consisting in the inactivation of
endogenous genes caused by insertion of the transgene
within its coding or regulatory regions.
Transgenic technologies are mainly used to assess the
effects of expressing the transgene, and to generate in vivo
readouts of the activity of regulatory regions or of signal-
ling pathways. Transgenic expression provides indications
as to the function of the expressed sequence. According to
the regulatory regions used for generating the construct,
expression can be ubiquitous or tissue-specific, or it can
occur in tissues/cell types, which do not normally express
the corresponding protein (ectopic expression). Particu-
larly useful is the ability to control transgene expression so
that it can be induced or repressed at will, in order to avoid
toxic or even lethal effects of permanent expression and to
more closely reproduce the effects of acute gene activation.
Gene function studies are usually performed by
expressing the transgene at high levels (overexpression),
followed by the analysis of the phenotype of the resulting
mice. See also: Transgenic Mice Production
Transgenic mice are also useful to assess the function-
ality of regulatory regions or the activation of specific sig-
nalling pathways. Both approaches are based on the use of
a so called ‘reporter gene’. This is a sequence encoding for a
protein whose expression is readily detected either by
fluorescence or via its enzymatic properties. The presence,
abundance and cell/developmental stage specificity of the
reporter gene expression can thus be easily characterised.
This approach has been widely used to test the activity of
complex transcriptional regulatory regions, which cannot
be faithfully tested in cell culture assays. The ‘reporter gene
cassette’ is placed under the control of the regulatory
region(s) under study, and microinjected into mouse zyg-
otes to obtain transgenic mice where the reporter gene
activity can be analysed in detail.
If on the other hand the ‘reporter gene’ is placed under the
control of a regulatory region already characterised as being
responsive to the activation of a specific signalling pathway/
transcriptional program, this approach allows toanalyse the
pathway activation under specific conditions such as during
development or, for example, under pathological stimuli.
Thus, the presence and position of reporter-positive cells
indicate that pathway activation has occurred and that a
specific signal has been used. This approach has been suc-
cessfully used for the Wnt-b-catenin and for the Notch
pathways (Maretto et al., 2003; Vilas-Boas et al., 2011).
Targeted mutagenesis: taking genes away
In addition to the problem of random integration, con-
ventional nuclear injection technology can only add – not
subtract – genetic material. In genetic terms, this means
that transgenic mice are only useful for the analysis of
dominantly transmitted phenotypes.
By 1988, an independent transgenic technology – known
as gene targeting – was developed that allows to disrupt,
eliminate or modify any cloned gene, in a ‘targeted’ way
(Mansour et al., 1988). This method is widely used to
determine gene function by examining the phenotype of
mice/embryos lacking the gene of interest, or expressing an
alternative form of it; this approach is often useful to
generate a mouse model for human diseases caused by loss
of gene function (recessively transmitted phenotypes).
See also: Knockout and Knock-in Animals; Mouse
Knockouts: Modifying the Mouse Genome by using
Embryonic Stem Cells; Mutagenesis: Site-specific
Targeted genome manipulation was achieved by coup-
ling two innovative tools: homologous recombination and
embryonic stem cells (ES) (Thomas and Capecchi, 1987;
Evans and Kaufman, 1981). The fact that both Mario
Capecchi and Martin Evans have won the Nobel Prize in
Physiology or Medicine in 2007, together with Oliver
Smithies, ‘for their discoveries of principles for introducing
specific gene modifications in mice by the use of embryonic
stem cells’ illustrates well the importance of this
development.
ES cells are derived from the ICMof a blastocyst and can
be manipulated without losing their differentiation poten-
tial to be then reintroduced by microinjection into a host
blastocyst embryo. The injected blastocyst is implanted in
the uterinehorns of a fostermother andallowed todevelop.
The ES cells will contribute to the tissues of the developing
embryos including the germ line, leading to the birth of
‘chimeric’ pups, formed partly by cells of the donor embryo
and partly by the injected ES cells.
The ES cells genome can be transmitted to the progeny,
therefore any genetic modification obtained in ES cells can
be passed on to generate a strain of mutant mice.
However, homologous recombination is a rare event in
mammalian cells and requires appropriate selection and
screening methods. To obtain ES cell clones genetically
modified at a specific locus, a DNA sequence containing
the desired mutation can be engineered as to contain
regions of homology flanking the gene of interest, then
introduced into ES cells. ES cell clones undergone hom-
ologous recombination will show integration of the
recombinant sequence into the host genome precisely at the
site of homology due to the exchange of genetic material,
resulting in loss of the wild type gene from the host DNA.
Gene inactivation via gene targeting is currently an
essential tool to define gene function through the pheno-
typic analysis of mutant embryos and mice. Often the
results confirm the predicted functions, but even more
often these studies reveal unexpected new roles and/or
functional in vivo redundancy not predicted by previous
in vitro studies or by sequence/structure-based gene clas-
sifications. This has been for example the case of genes
encoding for cytokines and interleukins (ILs), soluble
peptides involved in the control of immune functions.
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In vitro, IL-4 promotes the growth and differentiation of
many hematopoietic cells in vitro, and directs the
immunoglobulin (Ig) class switch to IgG1 and IgE. How-
ever, surprisingly in the IL-4 null mice, among the first
germ-line targeted mutation to be published (Ku¨hn et al.,
1991), the number and differentiation of both B and T cells
were unchanged, although the serum levels of IgG1 and
IgE were strongly reduced, showing how only some of the
in vitro properties of IL-4 are critical for the physiology of
the immune system in vivo. Indeed, functional redundancy
appears to be more the rule than the exception in the
mammalian genome, providing protection against the
adverse consequences of mutations. See also: Cytokines
The advent of conditional mutagenesis
Gene targeting has tremendously expanded our knowledge
and revolutionised our way of thinking about genetics.
However, it does not allow the functional analysis of those
genes, which also maintain defined functions in the adult
organism. Moreover, the lack of a given gene product
during development can bring about adaptation phenom-
ena that may obscure the phenotype. The solution to this
problem has come with the application of conditional
mutagenesis mediated by the Cre recombinase, an enzyme
derived from the bacteriophage P1. See also: Cre–lox-
Inducible Gene Targeting
Cre recombinase canmediate the excision of a portion of
DNAflanked by its recognition sequence, called loxP sites.
Thanks to DNA looping, the length of the intervening
sequence can be very long, up to 3–5 centi-Morgan. Briefly,
a ‘conditional allele’ is generated by homologous recom-
bination in ES cells by inserting two loxP sites flanking at
least one essential exon. These alleles are functional but
amenable toCre-mediated deletion and inactivation. Cre is
expressed by transgenesis or by viral transduction, either
ubiquitously or in specific tissues and/or inducibly, and
deletes the loxP-flanked sequence thus triggering gene
inactivation. A great number of Cre transgenic mice have
been generated that express the enzyme in specific tissues,
cell types or developmental stages, and/or where Cre
expression or function can be controlled by exogenous
molecules, and most of them are available to the scientific
community.
The Cre–lox system can also be used to activate trans-
genes whose regulatory sequences have been blocked by a
‘STOP’ cassette flanked by loxP sites: in this case Cre
activation will delete the stop sequence, thus activating
gene transcription. This approach, widely used in the
tumour field (see section ‘Tumour models’), has been very
useful for cell lineage studies, whereby a fluorescent
reporter gene with a lox-stop-lox sequence is introduced in
the germ line, and becomes activated upon Cre expression
and deletion of the STOP cassette, thus leading to lineage-
specific fluorescence positivity.
The Cre–lox system allows the generation of even very
large chromosomal deletions or translocations. Owing to
the great genomic distances involved, in this case the loxP
sites have to be separately introduced into the ES cells
genome, together with suitable markers allowing to select
for the rare recombination event. See also: Translocation
Breakpoints in Cancer
New frontiers in the manipulation of the
mouse genome
The recent discovery of the RNA interference pheno-
menon has allowed new approached to gene inactivation,
whereby transgenic mice expressing shRNAs able to target
specific genes fordegradation canbegenerated, bypassing the
need for the tedious passages involved in the homologous
recombination in ES cells and their injection in mouse
embryos See also: RNA Interference (RNAi) and
MicroRNAs
However promising, technical limitations regarding off-
target effects and silencing of the interfering RNA have so
far diminished the enthusiasm for this approach. Recently,
DNAses that can be targeted to specific genomic sequences
have been used to mutagenise genes either in the mouse
zygote or in somatic cells. See also: Meganucleases and
Their Biomedical Applications
Mouse as a Model for Diseases
The approach to manipulate the expression/sequence of a
gene that represents themouse ortholog of a disease gene in
human has been used to unequivocally demonstrate the
cause–effect relationship between a knownmutation and a
disease phenotype.Mousemodels of diseases aremoreover
precious to identify pathogenic molecular mechanisms
and, on the long term, to test and validate novel therapeutic
strategies. Here, we illustrate a few key examples in dif-
ferent categories of human diseases, both inherited and
acquired.See also:HumanDisease:MouseModels;Mouse
as a Model for Human Diseases
Classic monogenic diseases
A full collection of human monogenic diseases, the
description of their phenotype and the known genetic
mutations in human is contained in the database OMIM
(http://www.ncbi.nlm.nih.gov). Mouse models for each of
these human conditions have been or are being generated.
An example that illustrates at the same time the usefulness
of this approach and its limits is the generation of a mouse
model for cystic fibrosis. Cystic fibrosis is caused by
mutations inactivating theCFTR gene, which encodes for a
Cl2 ion channel present at the apical membrane of epi-
thelial cells, and is characterised by airways, intestinal and
reproductive organs obstruction due to dense secretions
and water flux impairment. The intestinal phenotype was
perfectly reproduced in CFTR null mice, which however
did not show any alteration of the respiratory airways or of
the reproductive organs due to anatomical and physio-
logical differences between mouse and man. Attempts to
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correct the CFTR defect are rapidly advancing thanks to
the use of this model (Ostedgaard et al., 2011).
Other two important examples are the dystrophin null
(MDX) and the a-sarcoglycan null models of muscular
dystrophy (MD). Although these mice exhibit a muscular
phenotype that does not well recapitulate the degeneration
seen in MD patients, they have provided important new
knowledge on muscle regeneration and muscle stem cells.
Moreover, they have been a key instrument to test the
regeneration properties of grafted cells (Galvez et al., 2006;
Tedesco et al., 2011; Goehringer et al., 2009) or the efficacy
of pharmacological treatments (Minetti et al., 2006; Hori
et al., 2011). Themouse line devoid of laminin-a2, a protein
of the basement membrane, has been extensively used as a
model of MD to examine the effectiveness of gene therapy
approaches or administration of pharmacologic and
trophic factors (Kumar et al., 2011).
Mice knock-out for the methyl-DNA-binding protein
gene Mecp2 partly reproduce the neurological and cogni-
tive impairments of childrenwith theRett Syndrome, a rare
but devastating congenital condition caused by mutations
in Mecp2. Surprisingly, the generation of a new strain of
animals in which theMecp2 mutation could conditionally
be eliminated showed that restoration of the wild type gene
even in adult life could revert some of the cognitive and
neurological defects (Guy et al., 2007;Gadalla et al., 2011),
with striking therapeutic implications.
Many other mouse models for important diseases have
been generated with the same general purpose to provide a
model to test therapeutic approaches. For instance, lack of
collagen-VI leads to a specific form of MD, in model mice
and human. Mice have been used to revert the muscular
dysfunction and prove the validity of pharmacological
therapies (Grumati et al., 2010).Mice defective for laminin-
5 display the phenotype of Epidermolysis Bullosa, a severe
congenital skin pathology. Transplantation of modified
epidermal stem cells, re-expressing laminin-5, has been
shown to correct the defect and support the regeneration of
a nearly normal skin (Mavilio et al., 2006). Mouse models
of Metachromatic Leurodystrophy, a severe storage dis-
ease affecting the central nervous system, are paving the
way to testing new therapies (Miyake et al., 2010; Lattanzi
et al., 2010). It is expected that in the near future models of
each monogenic or polygenic disease will be available for
testing. See also: Cystic Fibrosis; Duchenne Muscular
Dystrophy; Rett Syndrome
Genetic diseases leading to developmental/
congenital malformations
Babies are born with congenital diseases at a low but
consistent frequency. Inborn errors and diseases are not
usually life-threatening, however they pose seriousmedical
and social problems.
The study of the impact of physical/chemical insults
(known as ‘teratogens’) on development is usually con-
sidered the subject of ‘teratology’. The mouse embryo is
still used for studies analysing the effect of teratogens
applied to pregnant females or cultured whole embryos.
Although providing limited scientific information, ter-
atology helps to define parameters andmeasures to prevent
congenital diseases.
Investigating the role of genes in normal development,
and in parallel the cellular and tissue dysfunctions that are
caused by their mutations, is instead the subject of devel-
opmental genetics. Since human embryo cannot be studied
for evident ethical reasons,we heavily dependon themouse
embryo for these studies. This is facilitated by the large
number of both spontaneous and experimentally generated
mutant mouse strains already available (Rosenthal and
Brown, 2007). Themouse embryo ismoreover amenable to
studies of cell lineage and pathway activation via the
transgenic expression of fluorescent proteins combined
with the Cre–Lox conditional systems (see section ‘The
advent of conditional mutagenesis’). See also: Human
Developmental Molecular Genetics
Developmental genetic focuses on specific organs and
structures, and often information derived from one
experimental system cannot be directly extended to other
systems. The two main considerations, or concerns, guid-
ing developmental geneticists are:
1. To identify a simple system, easily accessible to
experimental procedures, and test the role of individual
genes. This is the case of the limbs, the tooth, the palate.
2. To identify genes causing human congenital diseases
and malformations, and to generate a mouse model
harbouring the correspondingmutation.This is the case
of genes affecting the skeleton, the limbs, the skin and
the neural tube.
Significant advances have been made in several dir-
ections: cardio-vascular development and the corres-
ponding heart congenital syndromes (Snider and Conway,
2011); craniofacial development and the corresponding
malformations, such as holoprosencephaly and cleft lip/
palate (Gritli-Linde, 2008; Schachter and Krauss, 2008);
limb development and the corresponding limb mal-
formations (Zeller, 2010); ectoderm development and skin
dysplasia (Vanbokhoven et al., 2011); the closure of the
neural tube and the neural tube defects such as Spina Bifida
(Greene and Copp, 2009); and kidney development (Ly
et al., 2011). For each of these conditions, a number of
relevant genes have been identified and studies. See also:
CraniofacialAbnormalities:Molecular Basis; Craniofacial
Defects andCleft Lip and Palate; Dysmorphic Syndromes;
Paediatric Congenital Heart Disease; Skeletal Dysplasias:
Genetics
Congenital diseases can result from altered cell migra-
tion during development; this is the case of neural crest
cell-related conditions (Cordero et al., 2011; Theveneau
andMayor, 2011), specific neurological disease (Liu, 2011;
Valiente and Marı´n, 2010) and hypogonadotropic hypo-
gonadic syndromes (Hardelin and Dode´, 2008). See also:
Neural Crest: Origin, Migration and Differentiation
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Metabolic disorders represent large set of rare diseases,
often recessive, caused by the absence or inactivity of an
enzyme, and the consequent accumulation of specific
metabolites in tissues and organs. Animal models have
been generated and hopefully will soon be used to initiate
pre-clinical studies to attempt restoring or bypassing
enzymatic functions (i.e. glycogenosis-type Ia – Grinshpun
et al., 2010). It is important to note that, in the case of
metabolic diseases, the mouse model may not faithfully
recapitulate the human condition, since mice and humans
are metabolically different. See also: Metabolism: Heredi-
tary Errors
Tumour models
Although cancer is most often not inherited, it can never-
theless be considered a genetic disease since it is brought
about bymutations in key geneswith either a pro-oncogenic
(oncogenes) or an anti-oncogenic (tumour suppressors)
function. See also: Oncogenes; Tumor Suppressor Genes
Typically, mutations in oncogenes generate aberrantly
active or overexpressed proteins, whereas loss of function
mutations affect the activity or expression of tumour sup-
pressor genes. Thus, the generation of transgenic mice
expressing/overexpressing oncogenes, either in their wild
type form ormutated, has represented an excellent method
to study tumour onset and progression and, later, to test
therapeutic treatments. Indeed, the ability of a predicted
oncogene to induce tumour onset when overexpressed in
transgenic mice is considered the gold standard to classify
it as a bona fide oncogene. Moreover, transgenic models
have been instrumental to demonstrate that the tumour
transformation process requires the interaction between
more than one oncogene or between oncogenes and onco-
suppressors (the multi-hit theory of tumour transforma-
tion, Knudson, 1971), thus confirming data previously
obtained in vitro. See also: Tumor Formation: Number of
Mutations Required
Conversely, gene targeting has allowed to reproduce
mutations in onco-suppressor genes. Among the first genes
subject to this analysis has been the famous onco-
suppressor TP53. Its targeted inactivation has allowed not
only to demonstrate and dissect its onco-suppressive
functions, but also to define its preferential target tissues
and its tissue-specific interactions with oncogenes such as
for example c100-myc. Further studies, introducing spe-
cific mutations found in human tumours in the tp53 allele,
have allowed finally to demonstrate their dominant nega-
tive role.Again, the ‘status’ of bona fide tumour suppressor
is granted only if its ablation leads to tumour development.
See also: Cell Cycle Control: Molecular Interaction Map;
P53 and Cell Death
Almost infinite combinations of the different approaches
used to manipulate the mouse genome are possible,
allowing the generation of more and more precise
tumourigenesis models. For example, the expression of the
transgenic oncogene must be activated by Cre expression/
activity induction by deleting a stop sequence (see section
‘The advent of conditional mutagenesis’). The generation
of mice expressing the K-Ras oncogene under this Cre-
mediated control has allowed to appreciate the tissue spe-
cific functions of this oncogene, able to induce tumours
only in the lung when activated alone (Guerra et al., 2003).
Conversely, sporadic K-Ras activation triggered by ade-
noviral-mediated delivery of Cre recombinase to lung epi-
thelial cells gave rise to pulmonary adenocarcinomas with
100%penetrance, showing that a sporadic Rasmutation is
sufficient to elicit lung tumourigenesis (Meuwissen et al.,
2001). Finally, the combination of oncogene expression
with the inactivationof genes thought to act downstreamof
it allows to finely dissect the oncogenic pathway thus
identifying potential new therapeutic targets. This
approach has for example recently allowed to identify c-
Raf as an essential mediator ofK-Ras-driven nonsmall cell
lung carcinoma (Blasco et al., 2011).
Large-scale mutagenesis to find new disease
genes or modifiers
Spontaneous mutations in mice may result in benign
phenotypes such as variable coat colours, or in disorders
that have similarities to diseases in man. However, spon-
taneous mutations occur at very low frequencies. Long-
time efforts have been initiated with the general aim to
generate an unbiased collection of cells and mice that
harbour mutations in each of the approximately 25 000
genes in themammalian genome. The goal is to saturate the
mouse genome with mutations causing loss or gain of
function in each gene, with the possibility to later establish
a line of animals and examine their phenotypes (Cartwrigh,
2009). Consortia for large-scale mutagenesis have been
initiated in the USA, Europe and Japan, with different
strategies and tools:
. Chemical mutagens that induce preferential types of
mutations, at a given frequency, randomly in the gen-
ome. Erythro-nitroso-urea (ENU) is a potent alkylating
agent and induces mainly missense point mutations.
ENU is being used tomutagenise themale germ cells and
generate from the treated males a progeny that is
screened for interesting phenotypes with a panel of
morphological, biochemical and behavioural tests. A
caveat: this strategy mostly detects dominantly trans-
mitted phenotypes, and exclusively those affecting non-
essential developmental processes and organs.
. Gene-trap insertional mutagenesis, to introduce specific-
ally engineered sequences into the genome of mouse ES
cells. The sequence usually contains a reporter gene, to
facilitate the detection of interesting expression patterns,
and a splicing sequence that serves to ‘trap’ an exon of an
endogenous gene. The randomly trapped genes in most
cases are also ‘null’, therefore the selected ES cells can be
used to generate heterozygous (first generation) and
homozygous (second generation) mice. Caveat: the
selection of the ES cells is still based on gene-driven
hypothesis or interesting expression patterns, the
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generationofmutantmice is time consuming and the gene
inactivation is sometimes incomplete, making the inter-
pretation of phenotypes sometimes difficult.
. Use of transposon-type elements, such as ‘sleeping
beauty’ or ‘piggyBac’ to extensively mutagenise the
mouse genome, by random insertion of these elements in
ES cells (Landrette and Tian, 2011). These approaches,
applied to ES cells, have the same advantages and cav-
eats of gene-trap strategies. However, they can also be
used for somatic cells genetic, and in this case only few
mouse strains need to be generated, that can sub-
sequently be used in a variety of ways.
. In vivo use of RNAi libraries targeting all known genes.
This approach has the caveat of incomplete loss of gene
function and possible off-targets effect that need to be
monitored and excluded to avoid serious data mis-
interpretation. See also: Deconstructing Gene Function
through ENU Mutagenesis; Mouse N-ethyl-N-nitro-
sourea (ENU) Mutagenesis; Transposons as Natural
and Experimental Mutagens
The Mouse as Valuable In Vivo
Experimental Tool
Below are reported a few examples ofwhat ismade possible
by the new technologies that allow to genetically manipu-
late the mouse genome, not necessarily entailing disease
models.
Genetically expressed fluorophores and
imaging
The combination of genetically coded fluorophores
that are nontoxic, monomeric and do not require exogen-
ous substrates or cofactors, with new imaging techniques,
has allowed to dynamically visualise subcellular bio-
logical process, such as photo-activation and photo-con-
version (Nowotschin et al., 2009).With the combination of
these tools, the visualisation of single cells and their bio-
chemical and genetic properties within embryonic and
adult tissues is now feasible. See also: Fluorescence
Microscopy
One fascinating example of the application of advan-
ced fluorescent imaging is the possibility to monitor the
migration of young neurons during brain development,
when combined with intrauterine electroporation through
the embryonic cortex (Borrell et al., 2005). This method
is used to introduce expression or silencing vectors, com-
bined with the green fluorescent protein for the visual-
isation. This approach was instrumental to establish
several routes and modes of migration and their molecular
regulation.
The use of genetically coded fluorophores can be com-
binedwith theuse ofCre–Lox systems to turn-onor turn-off
fluorophore expression in specific cell types. Furthermore,
the nucleotide analog BrdU can be injected and used to
monitor cell proliferation and exit from the cell cycle,
in vivo. In a recent work, Encinas et al. (2011) have used
these methods to precisely determine how many neurons
and of which type are generated by neural stem cells in the
post-natal hippocampus, and defined their fate. The results
represent a key advancement in the field of stem cells and
have a great impact on our knowledge on adult neuro-
genesis. See also: Cerebral Cortex Development; Neural
Stem Cells
Finally, recent work illustrates the possibility to dissect
molecular pathways and their regulation directly in
embryonic tissues (Grigoryan et al., 2008; Beronja et al.,
2010), bypassing the use of genetically modified animals.
This takes advantage of the fact that the ectoderm, the
embryonic precursor of tissues like skin, hair, glands,
cornea, being the most superficial layer in a developing
embryo, is easily accessible to vectors delivering exogenous
sequences upon a simple intra-uterine injection. The effect
of their expression on the morphogenesis and maturation
of ectoderm derivatives can then be observed. This
experimental strategy is a very promising new avenue
towards a deep comprehension of the molecular pathways
controlling multi-cellular organisations. See also: Brain:
Neurodevelopmental Genetics; Neural Crest: Origin,
Migration and Differentiation; Signal Transduction Path-
ways in Development: Wnts and their Receptors
Insights into mammalian development
The use of the mouse as a model of mammalian develop-
ment has opened extraordinary avenues. Today we can
investigate the following developmental features, previ-
ously established in Drosophila, also in mammalian
embryos:
. Body plan: a set of early positional information (usually
as gradients of signals or specific cell-cell contacts) that
defines anterior versus posterior, dorsal versus ventral;
left versus right, and defines the general identity and
number of segmental structures (head, thorax and tail).
Mutations in genes controlling the identity of large
structures are called ‘homeotic’.
. Pattern: the positional organisation of group of cells
that, apparently equal, are in fact distinct in their pro-
spective fate. The difference in fate relies on cellular–
molecular differences, established in earlier times.
Patterns are usually plastic in early stages and became
fixed at later stages.
. Morphogenesis: the acquisition of specific 3D organ-
isations and shapes from more simple organisation.
Examples are neural tube closure, heart looping, exten-
sion and fusion of the pharyngeal arches and limb
outgrowth. Once initiated, morphogenesis is usually
irreversible.
. Cell communication: groups of cells establish dialogues
during development via diffusible molecules (signalling
at distance) and via cell surface/adhesion molecules
(signalling by contact). Extensive cell communications
occur not only between the ectoderm and the mesoderm
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during development, guide morphogenesis and cell
migration, but also takes place in the control of
homeostasis of adult tissues and cancer formation.
See also: Mouse Early Development: Molecular Basis
The typical questions that mouse developmental gen-
eticists can now ask are:
. Which molecules make up a pattern, how is this estab-
lished and maintained?
. How is the morphogenesis of a specific structure
organised and executed? Which precise signals and cell
interactions take place?
. How do cells coordinate their proliferation, migration,
differentiation and programmed death?
. Howdo cells migrate, where to, and in response towhich
directional clues? Migration is typical of neurons during
brain development, of neural crest cells during for-
mation of craniofacial skeleton, and primordial germ-
line cells during the colonisation of the gonads.
. Is cell fate determined intrinsically or by the social con-
text? Can cell fate be modified? See also: Apoptosis:
Inherited Disorders; Mammalian Embryo: Branching
Morphogenesis; Neural Crest: Origin, Migration and
Differentiation; Neuronal Migration; Signal Transduc-
tion: Overview
Results from developmental genetic approaches in the
mouse have proven that the general body plan is main-
tained during development of all Vertebrates, and that to a
large extent the same genes and signals are used to establish
it. This is not totally surprising, as we now recognise that
the human and Vertebrate genomes are highly conserved,
especially in the protein coding, micro-RNA and key
regulatory elements.
A striking example of a conserved molecule for a con-
served process is Pax6, a homeodomain gene essential for
eye formation from flies to man (Gehring and Ikeo, 1999).
The forced expression of the mammalian Pax6 in a Dros-
ophila embryo can induce the formation of an ectopic eye
in the adult fly.Notably, the aberrant eye is of aDrosophila
type and not a mammalian type. This means that certain
genes have conserved a general ‘master developer’ function
across evolution, and that the rest of the genome acts as an
‘executor’ of the master program, thus defining the details.
A converse example is the Drosophila engrailed gene,
able to restore normal cerebellum development in mice
devoid of the mouse hortholog En1 (Hanks et al., 1998),
even though the fly does not possess any structure in its
nervous system resembling a mammalian cerebellum.
Similarly, the distalless gene of the fly is essential to allow
appendages such as mouthparts, antennae and limbs to
extend and grow. The distalless mouse and human horto-
logs are essential for normal limb development, and
their disruption causes limb congenital malformations
(Panganiban and Rubenstein, 2002; Merlo et al., 2002).
Intriguingly however, the fly and the Vertebrate limbs have
nothing in common except that they protrude out of the
body. This ‘master’ function has thus been maintained
across evolution. See also: Evolutionarily Conserved
Noncoding DNA; Genome Evolution: Overview; Hox
Genes: Embryonic Development; Mammalian Embryo:
HoxGenes; Transcription Factors
Finally, as mentioned in section ‘Genetically expressed
fluorophores and imaging’, the use of fluorophores in the
mouse embryo has allowed us to appreciate the importance
and precision of cell migration, particularly in the per-
ipheral and central nervous system and of the neural crest.
The precise timing and location of the migratory processes
imply the existence of signals and signal receptors, guiding
the cells to the correct target tissues: a subject of intense
research.
The paradigm of cellular pluripotency and
reprogramming approaches
A new frontier in biomedical research is the possibility to
force somatic cells to de-differentiate, thus assuming the
features of pluripotent, or totipotent, stem cells (induced
pluripotent stem (iPS) cells). These cells can potentially be
used for a number of important applications such as tissue
regeneration and correction of genetic defects. For obvious
ethical reason, again the organism of choice to experiment
both iPS generation and their therapeutic application is the
mouse. Different approaches have been developed to con-
fer pluripotency to adult cells: somatic cell nuclear transfer,
parthenogenesis of unfertilised eggs, reprogramming by
cell fusion and, more recently, forced expression of key
transcription factors and/or the use of smallmolecules. The
team led by Yamanaka in 2006 first identified four tran-
scription factors (Klf4, Sox2, Oct4 and c-Myc) that could
reprogram mouse fibroblasts into pluripotent cells upon
retroviral transduction (Takahashi and Yamanaka, 2006).
These iPS exhibit themorphology and growthproperties of
ES cells and express ES cell marker genes. iPS can now be
generated from human somatic cells using nonintegrating
episomal vectors (Yu et al., 2009), taking these cells a step
closer to potential clinical use. Pluripotency of iPS cells can
be verified by microinjecting these cells into mouse blas-
tocysts and by analysing chimera formation and germline
transmission (mouse iPS cells), and teratoma formation
(human and mouse iPS cells) (Yamanaka, 2009). Several
cell types have been hitherto reprogrammed such as
dermal fibroblasts and keratinocytes from hair (Aasen and
Belmonte, 2010; Lowry et al., 2008). See also: History and
Ethics of Stem Cell Research
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